Zusammenfassung
Die rektalen neuroendokrinen Tumoren (NET) zeigen eine steigende Inzidenz in den letzten Jahren. Die meisten Tumoren sind asymptomatisch und werden im Rahmen von Vorsorgekoloskopien diagnostiziert. Da weniger als 1 % der Tumoren Serotonin produzieren, werden sie fast nie durch ein Karzinoidsyndrom entdeckt. In den Leitlinien der europäischen (ENETS) und nordamerikanischen Fachgesellschaften (NANETS) finden sich für die Kliniker, die diese Tumoren selbst in Zentren nur selten sehen, nützliche Diagnose- und Behandlungsalgorithmen. Grundlage für die Therapie sind die Tumorgröße und histopathologische Risikofaktoren für eine (Lymphknoten-)Metastasierung. Bei den < 1 cm, gut differenzierten rektalen NET wird die lokale Exzision endoskopisch oder chirurgisch empfohlen. Die Neoplasien mit einer Größe von 1–2 cm stellen eine prognostische und therapeutische Grauzone dar. Ab einer Größe von 1,5 cm muss eine onkologisch radikale Resektion als anteriore Rektumresektion oder abdominoperineale Exstirpation mit TME (totale mesorektale Exzision) erfolgen. Resektable Leber- und Lungenmetastasen gut differenzierter NET sollen in kurativer Intention chirurgisch angegangen werden.
Abstract
The incidence of rectal neuroendocrine tumors (NET) has increased in recent years. Most of these neoplasms are asymptomatic and are diagnosed by colonoscopy screening, which could be one of the reasons for the increasing occurrence. As less than 1 % of rectal NET produce serotonin they are practically never discovered due to a carcinoid syndrome. The current guidelines of the European (ENETS) and North American (NANETS) Neuroendocrine Tumor Societies support clinicians with useful diagnostic and treatment algorithms. The most important criteria for therapy are tumor size and histopathological risk factors for metastases. For well-differentiated rectal neuroendocrine neoplasms < 1 cm, local endoscopic or surgical excision is recommended. Due to the lack of evidence tumors sized 1–2 cm represent a grey area for prognosis and treatment. All NET > 1.5 cm must be excised by radical surgery as low anterior rectal resection or abdominoperineal extirpation with total mesorectal excision (TME). Resectable liver and lung metastases of well-differentiated NETs should be surgically treated with curative intent.
Literatur
Caplin M, Sundin A, Nillson O, Baum RP, Klose KJ, Kelestimur F, Plöckinger U, Papotti M, Salazar R, Pascher A, Barcelona Consensus Conference participants (2012) ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: colorectal neuroendocrine neoplasms. Neuroendocrinology 95(2):88–97. doi:10.1159/000335594. PubMed PMID: 22261972
Scherübl H, Klöppel G (2009) [Rectal carcinoids on the rise – update]. Z Gastroenterol 47(4):365–371. doi:10.1055/s-2008-1027930. Review. German. PubMed PMID: 19358064
Tsikitis VL, Wertheim BC, Guerrero MA (2012) Trends of incidence and survival of gastrointestinal neuroendocrine tumors in the United States: a seer analysis. J Cancer 3:292–302. doi:10.7150/jca.4502. PubMed PMID: 22773933; PubMed Central PMCID: PMC3390599
Konishi T, Watanabe T, Kishimoto J, Kotake K, Muto T, Nagawa H, Japanese Society for Cancer of the Colon and Rectum (2007) Prognosis and risk factors of metastasis in colorectal carcinoids: results of a nationwide registry over 15 years. Gut 56(6):863–868. PubMed PMID: 17213340; PubMed Central PMCID: PMC1954860
Modlin IM, Lye KD, Kidd M (2003) A 5-decade analysis of 13,715 carcinoid tumors. Cancer 97(4):934–959. PubMed PMID: 12569593
Choi HH, Kim JS, Cheung DY, Cho YS (2013) Which endoscopic treatment is the best for small rectal carcinoid tumors? World J Gastrointest Endosc 5(10):487–494. doi:10.4253/wjge.v5.i10.487. Review. PubMed PMID: 24147192; PubMed Central PMCID: PMC3797901
Kulke MH, Shah MH, Benson AB 3rd, Bergsland E, Berlin JD, Blaszkowsky LS, Emerson L, Engstrom PF, Fanta P, Giordano T, Goldner WS, Halfdanarson TR, Heslin MJ, Kandeel F, Kunz PL, Kuvshinoff BW 2nd, Lieu C, Moley JF, Munene G, Pillarisetty VG, Saltz L, Sosa JA, Strosberg JR, Vauthey JN, Wolfgang C, Yao JC, Burns J, Freedman-Cass D (2015) National comprehensive cancer network. Neuroendocrine tumors, version 1.2015. J Natl Compr Canc Netw 13(1):78–108. PubMed PMID: 25583772
Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M, Modlin IM (2011) The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am 40(1):1–18, vii. doi:10.1016/j.ecl.2010.12.005. Review. PubMed PMID: 21349409
Anthony LB, Strosberg JR, Klimstra DS, Maples WJ, O’Dorisio TM, Warner RR, Wiseman GA, Benson AB 3rd, Pommier RF, North American Neuroendocrine Tumor Society (NANETS) (2010) The NANETS consensus guidelines for the diagnosis and management of gastrointestinal neuroendocrine tumors (nets): well-differentiated nets of the distal colon and rectum. Pancreas 39(6):767–774. doi:10.1097/MPA.0b013e3181ec1261. PubMed PMID: 20664474
Hotz HG, Bojarski C, Buhr HJ (2011) [Neuroendocrine colorectal tumors. Surgical and endoscopic treatment]. Chirurg 82(7):607–611. doi:10.1007/s00104-011-2072-1. Review. German. PubMed PMID: 21656304
Rindi G, Klöppel G, Couvelard A, Komminoth P, Körner M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A, Scoazec JY, Wiedenmann B (2007) TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 451(4):757–762. PubMed PMID: 17674042
Scherübl H, Jensen RT, Cadiot G, Stölzel U, Klöppel G (2011) Management of early gastrointestinal neuroendocrine neoplasms. World J Gastrointest Endosc 3(7):133–139. doi:10.4253/wjge.v3.i7.133. PubMed PMID: 21860682; PubMed Central PMCID: PMC3159501
Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB (2008) One hundred years after „carcinoid“: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26(18):3063–3072. doi:10.1200/JCO.2007.15.4377. Review. PubMed PMID: 18565894
Klöppel G (2007) Tumour biology and histopathology of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 21(1):15–31. Review. PubMed PMID: 17382263
Park CH, Cheon JH, Kim JO, Shin JE, Jang BI, Shin SJ, Jeen YT, Lee SH, Ji JS, Han DS, Jung SA, Park DI, Baek IH, Kim SH, Chang DK (2011) Criteria for decision making after endoscopic resection of well-differentiated rectal carcinoids with regard to potential lymphatic spread. Endoscopy 43(9):790–795. doi:10.1055/s-0030-1256414. PubMed PMID: 21735371
Wang M, Peng J, Yang W, Chen W, Mo S, Cai S (2011) Prognostic analysis for carcinoid tumours of the rectum: a single institutional analysis of 106 patients. Colorectal Dis 13(2):150–153. doi:10.1111/j.1463-1318.2009.02090.x. PubMed PMID: 19863599
Wang YZ, Diebold A, Boudreaux P, Raines D, Campeau R, Anthony L, Woltering E (2014) Surgical treatment options for rectal carcinoid cancer: local versus low radical excision. Am Surg 80(1):31–35. PubMed PMID: 24401511
Colonoscopy Study Group of Korean Society of Coloproctology (2011) Clinical characteristics of colorectal carcinoid tumors. J Korean Soc Coloproctol 27(1):17–20. doi:10.3393/jksc.2011.27.1.17. PubMed PMID: 21431092; PubMed Central PMCID: PMC3053496
Kasuga A, Chino A, Uragami N, Kishihara T, Igarashi M, Fujita R, Yamamoto N, Ueno M, Oya M, Muto T (2012) Treatment strategy for rectal carcinoids: a clinicopathological analysis of 229 cases at a single cancer institution. J Gastroenterol Hepatol 27(12):1801–1807. doi:10.1111/j.1440-1746.2012.07218.x. PubMed PMID: 22743039
Zhou X, Xie H, Xie L, Li J, Cao W, Fu W (2014) Endoscopic resection therapies for rectal neuroendocrine tumors: a systematic review and meta-analysis. J Gastroenterol Hepatol 29(2):259–268. doi:10.1111/jgh.12395. Review. PubMed PMID: 24118068
de Mestier L, Brixi H, Gincul R, Ponchon T, Cadiot G (2013) Updating the management of patients with rectal neuroendocrine tumors. Endoscopy 45(12):1039–1046. doi:10.1055/s-0033-1344794. Review. PubMed PMID: 24163193
Boudreaux JP, Putty B, Frey DJ, Woltering E, Anthony L, Daly I, Ramcharan T, Lopera J, Castaneda W (2005) Surgical treatment of advanced-stage carcinoid tumors: lessons learned. Ann Surg 241(6):839–845; discussion 845–846. PubMed PMID: 15912033; PubMed Central PMCID: PMC1357164
Pavel M, Baudin E, Couvelard A, Krenning E, Öberg K, Steinmüller T, Anlauf M, Wiedenmann B, Salazar R, Barcelona Consensus Conference participants (2012) ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 95(2):157–176. doi:10.1159/000335597. PubMed PMID: 22262022
Goretzki PE, Starke A, Akca A, Lammers BJ (2012) [Surgery for neuroendocrine tumors of the gastroenteropancreatic system (GEP-NET)]. Internist (Berl) 53(2):152–160. doi:10.1007/s00108-011-2917-1. German. PubMed PMID: 22290318
McDermott FD, Heeney A, Courtney D, Mohan H, Winter D (2014) Rectal carcinoids: a systematic review. Surg Endosc 28(7):2020–2026. doi:10.1007/s00464-014-3430-0. Review. PubMed PMID: 24584484
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
O. Radulova-Mauersberger, S. Stelzner und H. Witzigmann geben an, dass kein Interessenkonflikt besteht.
Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.
Rights and permissions
About this article
Cite this article
Radulova-Mauersberger, O., Stelzner, S. & Witzigmannn, H. Rektale neuroendokrine Tumoren: chirurgische Therapie. Chirurg 87, 292–297 (2016). https://doi.org/10.1007/s00104-016-0153-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00104-016-0153-x